Citations

Clear

2960 citation(s) found for "Kim, P".

Daratumumab-based quadruplet therapy in functional high-risk relapse/refractory multiple myeloma patients induces changes associated with CD8 T cell signaling, activation and expansion
D’souza, Darwin , Hamilton, Mark , Chen, Zhihong , Cho, Hearn, Kumar, Shaji , Mulligan, George, Acharya, Chaitanya R. , Jayasinghe, Reyka G. , Foltz, Steven , Kim-Schulze, Seunghee

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 3955-3955

10.1182/blood-2025-3955 Get It

Abstract Background: The Multiple Myeloma Research Foundation (MMRF) and its partners launched the MyDRUG platform clinical trial (NCT03732703) to evaluate the safety and efficacy of genomically-guided treatments for functional high-risk relapsed/refractory myeloma patients (fHRMM). fHRMM patients with no discernible activating mutations and who had received 1-3 prior therapies (exposed to at least one proteasome inhibitor and an IMiD) were given a combination of daratumumab (D), ixazomib (I), pomalidomide (P) and dexamethasone (d) (D-IPd) quadruplet therapy. The goal of this study is to evaluate the immunomodulatory effects of daratumumab-(anti-CD38)-based therapy on fHRMM patients enrolled in the MMRF-sponsored MyDRUG umbrella clinical trial over the duration of therapy and to correlate immune changes with patient response immediately following the first two cycles of therapy. Methods Bone marrow (BM) aspirates were collected at baseline (BL) prior to therapy, at the end of 2 cycles (EOC2), 4 cycles (EOC4) of the quadruplet therapy and at the end of treatment (EOT) or progressive disease (PD). CD138-negative bone marrow mononuclear cells were isolated for profiling the immune microenvironment using scRNAseq, scTCRseq and CyTOF. Results Single-cell RNA and TCR profiles were generated from ~90,000 cells across 41 samples from 16 subjects. scRNAseq identified CD3+ T cells, NK cells, classical and non-classical monocytes and B cells. CD8+ T cells were further resolved into their subsets including precursor (TPEX) and terminally exhausted T cells (TEX) within the bone marrow microenvironment. Within the CD8+ T cell compartment, an expansion of the effector memory (TEM) cell population was observed following 2-cycles of therapy (EOC2). However, this TEM expansion was not sustained at timepoint EOC4. Towards the end of therapy, enrichment of precursors to putative exhausted and terminal dysfunctional effector memory cells (TEMRA) was observed. Subjects with partial (PR), very good partial (VGPR) and complete (CR) best overall responses showed an initial increase in TEM cells followed by a slow expansion of TEX and TEMRAcells over time. One patient with progressive disease (PD) maintained the highest LAG3 expression across the cohort among CD8 T cell subsets (TEMRA, EM) and CD4 Tregs at baseline while observing a significant upregulation of PDCD1 in CD4 Tregs and CD8 Naive cells by EOC2. Cell-cell communication network analysis identified secreted ligands between responders (CR/VGPR) and partial responders (PR) at EOC2. Samples with PR exhibited upregulation of signaling of TNF from the CD8 Naïve compartment (p=0.048, Wilcoxon), IFNG from the CD8 EM (p=0.073, Wilcoxon) and TEMRA (p=0.048, Wilcoxon) populations along with IFNG (p=0.073, Wilcoxon) from NK cells. CD14+ and CD14+16+ Monocytes on the other hand showed enrichment of LGALS9 (p=0.03 (CD14+), p=0.048 (CD14+CD16), Wilcoxon) in the PR group at EOC2 relative to responders. Finally, longitudinal tracking of T cell clonality showed preferential progressive expansion of TEMRA cells after the therapy. We mapped hyperexpanded (more than 16 copies) clonotypes, presumed to be tumor-reactive, to various CD8+ T cell subsets. These hyperexpanded clonotypes are mapped to the TEMRA, TEX and TEM CD8+ T cells. Analysis of TCR repertoires clonality and diversity also demonstrated a reduced richness and increased clonality of CD8+ TCRs in responders. Summary/Conclusion These preliminary analyses of D-IPd quadruplet therapy of RRMM indicate that paired single cell RNA and TCR sequencing of BM T cells suggests a selective expansion of clonotypic CD8+ T cells. When considering patient response, the only PD patient profiled in this study maintained an exhaustive signature (LAG3, PDCD1) in multiple T cell compartments at BL. The differential expression of the receptor ligand pairs after treatment between different clinical response groups suggests an altered TME response that may inform future therapeutic stratification. These results support further explorations of rational combinations of targeted and immune therapies for greater efficacy in this disease.
Feasibility in the Detection of Nodal Metastatic Melanoma Using Intravital Microscopy
Fisher, Daniel T., Kim, Minhyung , Ma, Xiaoyi , Francescutti, Valerie , Kane, John M. , Evans, Sharon S. , Skitzki, Joseph J. , Gabriel, Emmanuel , Attwood, Kristopher M. , Ma, Xiaoyi

Mayo Clinic

No container title available | December 3, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-5161333/v1 Get It

Abstract While the clinical focus on the sentinel lymph node biopsy (SLNB) is the presence of intra- or extra-nodal metastases, preclinical studies suggest that tumor-draining SLNB-associated vascular architecture and adhesion properties are altered regardless of SLNB positivity. Human intravital microscopy (HIVM) has defined blood vessel abnormalities that may impact lymphocyte adhesion and systemic drug delivery at primary melanoma sites. In this pilot study of HIVM during melanoma SLNB, we sought to determine the feasibility of obtaining HIVM observations of SLNB-associated vessels. We successfully performed HIVM in all 20 SLNB patients, and 7 were found to have nodal micrometastases by standard pathology. HIVM was capable of identifying both functional and non-functional SLNB-associated vessels based on the presence or absence of fluorescent dye uptake, respectively. Comparing vessel characteristics as a secondary objective, no statistically significant differences were noted in the diameter, flow rate, functionality, or shear stress of SLNB-associated blood vessels between positive and negative SLNBs, which may likely have been a reflection of the minimal disease burden. Nonetheless, these initial observations provide the framework to optimize future trials of HIVM in cancer patients.
Safety, Efficacy, and Mid-Term Outcomes of Pulsed Field Ablation for Cavotricuspid Isthmus–Dependent Flutter: Real-World Data From a Major Health System Registry
Rodriguez, Juan F. , Vemulapalli, Hema Srikanth , Prajapati, Poojan , Muthu, Padmapriya , Kim, James Y. , Sorajja, Dan , Shen, Win‐Kuang , Masry, Hicham El , Valverde, Arturo M. , Munger, Thomas M. , Rodriguez-Riascos, Juan F , Vemulapalli, Hema S , El Masry, Hicham , Sardana, Mayank , Valverde, Arturo M , Srivathsan, Komandoor , Muthu, Padmapriya , Srivathsan, Komandoor , Kim, James

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | December 2, 2025 | Volume: 18 | Issue: 12 | Pages: No page available

10.1161/circep.125.014276 | PMID 41328574 Get It

BACKGROUND: Cavotricuspid isthmus (CTI) ablation is frequently performed either as a standalone procedure or in combination with pulmonary vein isolation. With the rapid adoption of pulsed field ablation for atrial fibrillation, it is essential to delineate the utility of this modality in treating CTI-dependent atrial flutter (AFL). This study aims to evaluate the procedural and clinical outcomes of CTI ablation using pulsed field energy. METHODS: We conducted a retrospective analysis of consecutive patients who underwent pulsed field ablation for CTI-dependent AFL between January 2024 and March 2025. The primary end points were acute procedural success, periprocedural complications, and CTI-dependent AFL recurrence during follow-up. RESULTS: A total of 132 patients underwent CTI nonthermal ablation. The median age was 69.5 years, and 27.3% were female. The Farawave catheter was used in 93.9% of cases, PulseSelect in 4.5%, and Sphere-9 in 1.5%. Acute block was achieved in 99.2% of patients, although 8 required adjunctive radiofrequency ablation to complete the line. Periprocedural complications included transient ST-segment elevation in 2 patients and transient conduction disturbances in 3. During a median follow-up of 114 days (n=131), 5 patients (3.8%) experienced recurrence of typical AFL. The 6-month typical AFL-free survival estimate was 93.6%. CONCLUSIONS: Pulsed field ablation appears to be a feasible and effective strategy for CTI-dependent AFL. However, anatomic variability may limit its universal applicability with current catheter designs. Although acute procedural success is high, the long-term durability of the CTI block and its comparative efficacy versus conventional thermal ablation remain areas requiring further investigation.
Plasma Exchange for the Treatment of Light Chain Cast Nephropathy: A Multicenter Study
Shincovich, Christina I, Kim, Raphael C. , McGee, Emma E. , Peterkin, Alexa Caroline , Pirovano, Marta , Wells, Sophia L., Chowdhury, Raad Bin Zakir, Chewcharat, Api , Wells, Sophia L., Chowdhury, Raad Bin Zakir, Yee, Andrew J , Leung, Nelson , Gupta, Shruti

Mayo Clinic

Journal of the American Society of Nephrology | December 1, 2025 | Volume: 36 | Issue: 10S | Pages: No page available

10.1681/asn.20254jkwxd2z Get It

Efficacy of a Combination Therapy of Montelukast and Antihistamines in Allergic Rhinitis: A Systematic Review and Network Meta-Analysis
Kim, Ji‐Sun , Stybayeva, Gulnaz , Hwang, Se Hwan , Stybayeya, Gulnaz , Hwang, Se Hwan

Mayo Clinic

Allergy, Asthma & Immunology Research | November 28, 2025 | Volume: 17 | Issue: 6 | Pages: 692

10.4168/aair.2025.17.6.692 | PMID 41330702 Get It

Glucagon-Like Peptide-1 Receptor Agonists and Chronic Cough
Kim, Ian , Vukkadala, Neelaysh , Barbu, Anca M. , Razura, Diego E. , Gallagher, Tyler J. , Li, Albert

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | November 26, 2025 | Volume: 152 | Issue: 2 | Pages: 163

10.1001/jamaoto.2025.4181 | PMID 41296333 Get It

Importance Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have become substantially more popular as a medication to treat obesity and type 2 diabetes (T2D). Despite their known association with gastroesophageal reflux disease and vagal nerve stimulation, the association between GLP-1RAs and chronic cough has not been previously studied. Objective To assess the clinical association between GLP-1RAs and chronic cough. Design, Setting, and Participants This large, multicenter cohort study used clinical records from a US-based collection of electronic medical record data from April 28, 2005, to April 15, 2025, from 70 health care organizations. Adults (≥18 years) with T2D and prescription of a GLP-1RA were identified. Additionally, groups with T2D and prescription of another second-line diabetes medication, including dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter 2 (SGLT2) inhibitors, and sulfonylureas were created. After propensity score matching for various demographic and clinical characteristics, adjusted hazard ratios (aHRs) and 95% CIs were calculated using Cox regression analyses to estimate the risk of new chronic cough or gastroesophageal reflux disease diagnosis. Exposure GLP-1RAs or other second-line diabetes medication. Main Outcomes and Measures Chronic cough. Results Cohorts included 427 555 individuals (mean [SD] age, 55.8 [13.8] years; 251 928 female individuals [58.9%]) with T2D who were prescribed a GLP-1RA and 1 614 495 individuals (mean [SD] age, 63.7 [13.3] years; 712 946 female individuals [44.4%]) with T2D who were prescribed another second-line diabetes medication. After propensity score matching, individuals prescribed a GLP-1RA had significantly increased risk of new chronic cough compared with individuals prescribed any non–GLP-1RA second-line medication (aHR, 1.12; 95% CI, 1.08-1.16), DPP-4 inhibitor (aHR, 1.18; 95% CI, 1.11-1.26), or sulfonylurea (aHR, 1.32; 95% CI, 1.24-1.40) but not compared with SLGT2 inhibitors (aHR, 1.03; 95% CI, 0.98-1.09). After removing patients with a previous diagnosis of gastroesophageal reflux disease from analysis, patients prescribed GLP-1RAs had significantly increased risk of chronic cough compared with those prescribed any non–GLP-1RA (aHR, 1.29; 95% CI, 1.17-1.42), DPP4 inhibitor (aHR, 1.36; 95% CI, 1.17-1.58), SGLT2 inhibitor (aHR, 1.14; 95% CI, 1.02-1.28), or sulfonylurea (aHR, 1.25; 95% CI, 1.09-1.42). Conclusions and Relevance This cohort study suggests an association between GLP-1RA use and chronic cough. Further research is needed to confirm the existence, strength, and mechanisms of this association.
Combining Pirfenidone With Mycophenolate Mofetil for Systemic Sclerosis–Related Interstitial Lung Disease (Scleroderma Lung Study III ): An Investigator‐Initiated, Multicenter, Randomized, Double‐Blind, Pl
Khanna, Dinesh , Spino, Cathie , Kleerup, Eric C., Harui, Airi, Ibrahim, Grace, Kim, Grace Hyun J. , Huang, Suiyuan, McLain, Richard, Tu, Yi‐Hsuan, Steen, Virginia , Weigt, S. Samuel , Lee, Joyce , Fischer, Aryeh , Scholand, Mary Beth , Gordon, Jessica , Dellaripa, Paul F. , Rosas, Iván O. , Hunninghake, Gary M. , Trojanowski, Marcin A. , Dematte, Jane E. , Hsu, Vivien , Domsic, Robyn T. , Raghu, Ganesh , Boente, R. , Roth, Michael D. , Investigators, the Scleroderma Lung Study III, Kim, Grace Hyun J , Nagaraja, Vivek , Silver, Richard M. , Gordon, Jessica K , Dellaripa, Paul F , Domsic, Robyn T , Mayes, Maureen D , Boente, Ryan D , Roth, Michael D , Khanna, Dinesh , Lee, Joyce S , Hunninghake, Gary M , Tashkin, Donald P. , Bernstein, Elana J. , Goldin, Jonathan , Nagaraja, Vivek , Simms, Robert W. , Mayes, Maureen D. , Investigators, the Scleroderma Lung Study III

Mayo Clinic

ACR Open Rheumatology | November 26, 2025 | Volume: 7 | Issue: 12 | Pages: No page available

10.1002/acr2.70126 | PMID 41294296 Get It

Objective Mycophenolate mofetil (MMF) can stabilize or improve lung function in systemic sclerosis–related interstitial lung disease (SSc‐ILD). We hypothesized that combining MMF with pirfenidone (PFD) would produce a significantly more rapid and/or greater improvement in lung function. Methods A randomized (1:1), double‐blind, placebo (PLA)‐controlled phase 2 trial was conducted in SSc‐ILD in which patients received PFD or PLA (801 mg three times daily) along with MMF (1,500 mg twice daily) for 18 months. The primary outcome was change in percent predicted forced vital capacity (FVC‐%). Linear mixed‐effects models assessed treatment differences in a modified intention‐to‐treat population. Results Only fifty‐one of 150 intended subjects (34%) were randomized (MMF+PLA, n = 24; MMF+PFD, n = 27). The FVC‐% improved from baseline to 18 months by 2.24 ± 1.35 (least‐squares mean [LSM] ± SEM) in the MMF+PLA group and 2.09 ± 1.28 in the MMF+PFD group (LSM treatment difference −0.14; P = 0.93). Median time to achieve a ≥3% improvement in FVC‐% was numerically faster in the MMF+PFD versus MMF+PLA group (12.3 vs 17.8 months, respectively), but the difference was not significant ( P = 0.33). For secondary outcomes, only the change over 18 months in the Patient‐Reported Outcomes Measurement Information System 29‐item physical function score, favoring MMF+PFD, reached statistical significance ( P = 0.04). Although other related patient‐reported outcomes (PROs) numerically favored the MMF+PFD group, as did quantitative high‐resolution computed tomography measures of ILD, the differences between groups did not reach statistical significance. Early withdrawals from study medication and adverse events of special interest were numerically greater with MMF+PFD (n = 8 vs 2 and n = 20 vs 7, respectively). Conclusion In this underpowered study, there was no statistically significant treatment difference in overall change in FVC‐% between groups. MMF+PFD was not as well tolerated as MMF+PLA.
Early Career Focus Among General Surgery Residents Pursuing Vascular Surgery Fellowship: A Multi-Institutional Study From the US ROPE Consortium
Cui, Christina L. , Murillo, Alyssa , Muca, Antonela , Hier, Zachary E., Burton, Erin, Richmond, Robyn, Kim, Young, Cortez, Alexander R. , Kim, Young

Mayo Clinic

The American Surgeon™ | November 24, 2025 | Volume: 92 | Issue: 5 | Pages: 1592-1598

10.1177/00031348251399200 | PMID 41277369 Get It

Background Recent studies suggest that general surgery (GS) residents perform more operations related to their future specialty compared with their peers. In this multi-institutional study, we examined the process of early specialization among GS residents pursuing a career in vascular surgery (VS). Methods Data from the US Resident OPerative Experience (ROPE) Consortium, comprising 20 Accreditation Council for Graduate Medical Education (ACGME)-accredited GS residency programs across the United States, were queried. Case volume and type were compared between GS residents pursuing vs fellowship and all other residents. Effect size was evaluated using Cohen’s d statistic. Effect size was considered large if d > 0.8, moderate if 0.5 ≤ d < 0.8, small if 0.2 ≤ d < 0.5, and inconsequential if d < 0.2. Results A total of 1343 GS residents graduated from 2010-2020 across all programs participating in ROPE, of which 135 (10.1%) pursued vs fellowship. Total major vascular case volume was significantly greater among residents pursuing vs fellowship (138 [100-207] vs 100 [80-139], P < 0.0001) with a large effect size (d = 1.81). Vascular cases reported in a surgeon chief role (27 [9-53] vs 10 [2-29], P < 0.0001, d = 0.76, moderate effect) and surgeon junior role (107 [79-154] vs 88 [62-118], P < 0.0001, d = 1.00, large effect) were also greater among GS residents pursing a vs specialty. Nearly all vascular operative categories demonstrated similar trends ( P < 0.01 each). Conclusions GS residents pursuing a vs fellowship perform more vascular cases compared with their peers. Given the differences in both surgeon chief and surgeon junior roles, career focus may begin as early as the junior resident years.
Lucid episodes in people with advanced dementia: characterizing caregiver reports to advance definition and measurement of episodes
Griffin, Joan M. , Bangerter, Lauren R. , Kim, Kyungmin , Finnie, Dawn, Liu, Yin , Gaugler, Joseph E. , Batthyány, Alexander , Frangiosa, Terry, Gaugler, Joseph E , Griffin, Joan M , Kim, Kyungmin , Lapid, Maria I. , Finnie, Dawn M., Gilmore‐Bykovskyi, Andrea L

Mayo Clinic

The Gerontologist | November 22, 2025 | Volume: 65 | Issue: 12 | Pages: No page available

10.1093/geront/gnaf282 | PMID 41275393 Get It

Abstract Background and Objectives Lucid episodes (LEs) in advanced dementia are characterized by spontaneous, transient recovery of functional abilities. Despite recent increases in research on this previously understudied phenomenon, standard definitional criteria are lacking, presenting challenges for research. Researchers have proposed a preliminary framework to guide uniform labeling and operationalization of salient data elements for investigating LEs and developing definitional criteria. This study leverages this framework to characterize reports of LEs from caregivers and advance their definition and measurement. Research Design and Methods Family caregivers (N = 259) completed an electronic survey with quantitative and open-ended questions about LEs they witnessed (N = 479 episodes). Respondents were purposively sampled for qualitative interviews. Open-ended question responses (n = 208) and in-depth interviews (n = 24) were analyzed using content analysis. Results Caregiver descriptions suggest that the content and context of LEs are heterogeneous. Descriptions included observable changes from baseline, with behavior or communication that was distinguishable from routine cognitive fluctuations. LEs were sometimes, but not always specified by logically organized actions; recognition or awareness of people, emotions, and surroundings; and insight of their cognitive limitations. Many LEs required deep personal knowledge to attribute it as a meaningful shift. Discussion and Implications Findings suggest that definitional features may universally specify a significant return of ability with more flexible criteria for how this return manifests in observed actions and domains of recovery (i.e., insight, function, and communication). The impact of LEs on observers may be better measured separately, although further research should explore this.
SHP2: A Redox-Sensitive Regulator Linking Immune Checkpoint Inhibitor Therapy to Cancer Treatment and Vascular Risk
Moreno, Sira , Lenz, S., Casso-Chapa, Bernardo , Paniagua-Bojorges, Angelica , Kim, Jung Hyun , Palaskas, Nicolas L. , Nead, Kevin T. , Samanthapudi, Venkata Subrahman K, Mejia, Gilbert, Hoang, O.N. , Lee, Jonghae , Lin, Steven H. , Herrmann, Joerg , Yusuf, Syed Wamique , Iliescu, Cezar , Beinart, Noah , Manisty, Charlotte , Fukai, Tohru , Ameri, Pietro , Nurieva, Roza , Hildebrandt, Michelle A T, Schadler, Keri , Le, Nhat‐Tu , Abe, Jun‐ichi , López Moreno, Silvia Fernanda , Hoang, Oanh , Iliescu, Cezar A , Fukai, Tohru , Ameri, Pietro , Schadler, Keri , Le, Nhat-Tu , Abe, Jun-Ichi , Lin, Steven H , Palaskas, Nicolas L , Nead, Kevin T , Lee, Jonghae , Kim, Jung Hyun , Lenz, Stefania Assunto, Wang, Guangyu , Yusuf, Syed Wamique , Ushio‐Fukai, Masuko , Hildebrandt, Michelle A.T. , Koutroumpakis, Efstratios , Kotla, Sivareddy , Lenz, Stefania Assunto

Mayo Clinic

Antioxidants | November 21, 2025 | Volume: 14 | Issue: 12 | Pages: 1388

10.3390/antiox14121388 | PMID 41462587 Get It

Src homology 2-domain containing protein tyrosine phosphatase 2 (SHP2), encoded by the Ptpn11 gene (Tyrosine-protein phosphatase non-receptor type 11), is a key downstream effector of PD-1/PD-L1 signaling and is likely important, in addition to immune modulation, in tumor development and vascular homeostasis. SHP2 conveys PD-1 mediated inhibitory signaling in T cells, and is emerging as a therapeutic target. Importantly, there is an association between immune checkpoint inhibitors (ICIs), immune-related adverse events (irAEs), and cardiovascular complications, underscoring the need to understand SHP2’s role in these processes. This review aims to summarize current knowledge on SHP2/PTPN11 biology, its role in immune regulation, cancer progression, and vascular homeostasis, and to discuss emerging therapeutic strategies targeting this pathway. The concept of using SHP2 inhibitors with immune checkpoint inhibitors (ICIs) is being investigated to address ICI resistance and to improve anti-tumor efficacy substantially. SHP2 is also being studied in non-cancer cell contexts, and signaling responses can differ by large magnitudes depending on the biological context and stimuli. Under normal circumstances, SHP2 promotes vascular homeostasis in endothelial cells (ECs) and myeloid cells and inhibits inflammation, and the reduction in SHP2 activity by oxidative stress, such as in atherosclerosis or diabetes, upregulates inflammation. In contrast, in response to radiation, the fibrotic response and subsequent lung injury were increased by endothelial SHP2 induction via Notch-Jag1 signaling. Vascular smooth muscle cells SHP2 act as a pro-atherogenic effector by enhancing ERK/MAPK signaling, and the upregulation of mitochondria localized SHP2 can also induce cellular senescence-associated inflammation by upregulating mitochondrial reactive oxygen species. Taken together, the two opposite signaling effects of SHP2 suggest that both the immune and vascular system responses appear to be more modulated by the redox, cell, and compartment-specific signaling of SHP2. More studies are needed for mitigating cardiovascular toxicity to patients, particularly with ICI-based treatment regimens.